Download Full Text (895 KB)
During the 2022 mpox outbreak, the CDC’s expanded access Investigational New Drug (IND) protocol created a practical barrier to the outpatient provision of tecovirimat. We rapidly implemented a tecovirimat prescription program for individuals infected with mpox to improves access to care.
Primary aim: describe how we rapidly implemented a program for increasing tecovirimat distribution in a metropolitan area.
Secondary aims: describe the patient population who received tecovirimat as treatment for mpox at our clinic and analyze several clinically relevant time intervals along the continuum of care delivery.
mpox, disparities, tecovirimat, investigational new drug, IND, outbreak, infectious disease
Infectious Disease | Medicine and Health Sciences
McCarthy, BA, Michael; Glowacki, DO, MS, Joe; Livinsky, PA, Rostislav; Taupin, MD, MHQS, Daniel; and Coppock, MD. MSCE, Dagan, "Removing Barriers to Tecovirimat for Mpox-infected Individuals via Novel Models of Care Delivery" (2023). Division of Infectious Diseases and Environmental Medicine Posters. 5.